INTI实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 00:08):

Stats
今日成交量	24 000.00
平均成交量	9 237.00
市值	17.94M
EPS	$0 ( 2024-03-29 )
下一个收益日期	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.21
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-11	Osman Ronald E	Buy	25 000	Common Stock
2023-05-05	Ronald E Osman Irrevocable Trust Iii	Sell	0	Common Stock
2023-05-05	Tpb 2012 Llc	Buy	0	Common Stock
2023-05-05	Tpb 2012 Llc	Sell	0	Common Stock
2023-05-05	Mcnulty James A	Buy	20 101 057	Common Stock

INSIDER POWER
-57.75
Last 91 transactions
Buy: 128 793 757 \| Sell: 121 688 284

Inhibitor Therapeutics, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Inhibitor Therapeutics, 财务报表

Annual	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.0176

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.0176

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0.0325

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.000803

Financial Reports:

No articles found.

Inhibitor Therapeutics,

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.